| INTRODUCTION
Portal hypertension drives the development of complications of cirrhosis, such as variceal bleeding, development of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome, as well as hepatic encephalopathy. 1, 2 Portal pressure, assessed by hepatic venous pressure gradient (HVPG) measurement, is an excellent predictor for the development of liver-related events and mortality. 3 Thus, current guidelines recommend the assessment of HVPG for prognostic and therapeutic indications in specialised centres with sufficient experience. [4] [5] [6] Clinically significant portal hypertension, which is defined by a HVPG of ≥ 10 mm Hg, is associated with the development of varices, hepatic decompensation and liver-related mortality. 3, 7 HVPG values ≥ 12 mm Hg identify patients at risk of variceal bleeding. 8 Achieving a decrease in HVPG is protective of variceal bleeding and hepatic decompensation [9] [10] [11] and even improves survival. 2 HVPG response is traditionally defined by a decrease in HVPG to ≤ 12 mm Hg or of ≥ 20% compared to baseline. 12 However, according to the Baveno VI consensus, a decrease in HVPG of ≥ 10% (or to ≤ 12 mm Hg) seems sufficient in primary prophylaxis. 2 Nonselective beta blockers (NSBBs) decrease the risk of variceal bleeding by reducing portal pressure, ie HVPG. 13 Previously, NSBBs such as propranolol or nadolol have been used, however, carvedilol is more effective in reducing HVPG 2,14-16 since it exerts both anti-a 1 and anti-b 1 /b 2 adrenergic activity. 17 Indeed, a meta-analysis showed that the mean relative HVPG reduction is 22% for carvedilol and 16% for propranolol. 18 Two randomised controlled trial (RCT) have rates were recorded among patients treated with a fixed dose of carvedilol 12.5 mg/d (10% vs 23%), without a difference in bleedingrelated and overall mortality. 19 In contrast, the second RCT by Shah et al showed comparable variceal bleeding rates and overall mortality. 20 The latter study included 168 patients with medium-large varices with 82 being randomised to carvedilol 6.25 mg twice daily with a shorter follow-up of mean 13.3 months. Importantly, in both studies, the haemodynamic response rate to carvedilol was not assessed.
We could previously demonstrate that 56% of nonresponders to propranolol respond to carvedilol. Patients, who did not achieve hemodynamic response (HVPG decrease ≥ 20% or to ≤ 12 mm Hg) to propranolol received carvedilol and patients who failed to respond to carvedilol were treated with EBL. The rates of variceal bleeding (propranolol: 11% vs carvedilol: 5% vs EBL: 25%) and mortality (propranolol: 14% vs carvedilol: 11% vs EBL: 31%) were lower in responders to NSBB treatment, when compared to nonresponders treated with EBL. 10 Recently, potential deleterious effects of NSBB treatment in patients with advanced cirrhosis and (refractory) ascites have been reported. 21, 22 However, other studies reported beneficial effects in similar patient populations. 23, 24 Interestingly, a study by Bang and co-workers reported a dose-dependent effect of propranolol treatment, 25 and thus, high NSBB doses might have contributed to the detrimental effects observed in the study by Serste and colleagues. 21 Thus, evaluating the lowest effective NSBB dose for achieving HPVG response is of high clinical relevance, especially for carvedilol which is associated with dose-dependent systemic vasodilation. 18 The primary aim of this study was to assess the dose-response relationship between different doses of carvedilol (6.25 
| Management of nonresponder to carvedilol
Nonresponders were treated with endoscopic band ligation according to national guidelines. 3 | RESULTS
| Characteristics of the study population
Within the study period, HVPG was measured in 676 patients. After applying in-and exclusion criteria, a final number of 72 patients without a history of variceal bleeding were included. (Figure 1 )
The median age was 54 (48-63) years. Thirty-six (50%) patients had alcoholic liver cirrhosis (abstinent for 6 months or longer), 15 
| Potential impact of ascites on efficacy and side effects of carvedilol
Carvedilol reduced HVPG more efficiently in patients without ascites than in those with ascites (Table S2) . Notably, 4 out of 6 patients, in whom the carvedilol dose could not be increased due to bradycardia and/or arterial hypotension had ascites. In addition, all 4 patients who did not agree to undergo a third HVPG measurement had ascites.
However, none of the patients had a systolic arterial pressure <90 mm Hg with carvedilol at the time of the final HVPG measurement.
| Predictors for carvedilol response
Twenty-four out of 71 (35%) patients had a drop in pulse rate of ≥25% at the final HVPG measurement. Of those 24 patients, a HVPG response (HVPG decrease ≥20% or to ≤12 mm Hg) was achieved in 11/24 (46%) patients, while in patients with a drop in pulse rate of <25% at the final HVPG measurement, HVPG response was observed in 27/47 (57%) patients (P = 0.4987).
The relative change in pulse rate was not significantly different between responders and nonresponders, both for HVPG drops ≥20% (P = 0.8176) and ≥10% (P = 0.8504, Table 2 and Table S3 ). Our results are in line with the HVPG response rates described in the literature: First, Banares et al showed that more patients achieved a HVPG response with carvedilol (54%) than with propranolol (23%).
In this study, the mean dosages of carvedilol and propranolol were 31 AE 4 mg/d (range, 12.5-50 mg) and 73 AE 10 mg/d (range, 10-160 mg), respectively. 16 Kim et al reported a response rate of 49% to carvedilol 12.5 mg/d. 30 Another study showed that carvedilol 25 mg orally has a greater portal hypotensive effect than intravenous propranolol (initial bolus of 0.15 mg/kg followed by a continuous infusion of 0.2 mg/kg). The HVPG response rates to carvedilol and propranolol were 64% and 14%, respectively. 15 We could previously show that among the propranolol nonresponders, 56% achieve a haemodynamic response with carvedilol (median 12.5 mg/d). 10 The greater reduction in HVPG in carvedilol compared to propranolol is obtained by the different mode of action with additional anti-a 1 adrenergic blockade.
Indeed, the effects of carvedilol are similar to the combination of propranolol and the a 1 -adrenergic blocker prazosin. 15, 16, 31 In a report on the predicted preferences for primary prophylaxis, EBL was the primary choice in 64% of patients and 57% of physicians. 32 In a post hoc analysis with 1198 patients with ascites, 29%
of them stopped NSBB intake during follow-up. 33 Bosch et al suggested that patients should be asked for drug-related adverse events including oedema, dizziness, bradycardia, hypotension, nausea and blurred vision. 17 In our study, carvedilol was also found to significantly decrease pulse rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure. In n = 6 patients the carvedilol dose could not be increased to 12. Since HVPG is not widely available, pulse rate is often used to titrate NSBB dose aiming at a 25% reduction or a minimum pulse rate of 55 per minute. 36 However, we found that changes in pulse rate are not a suitable surrogate parameter for HVPG response to carvedilol. Similarly, Garcia Tsao et al have reported that pulse rate does not correlate with changes in HVPG in patients treated with propranolol. 37 Interestingly, patients without ascites showed more pronounced changes to carvedilol 6.25 mg/d, regardless of the response criteria.
Increased vascular resistance to portal blood flow is the initial factor responsible for the increase in portal pressure and is partly modifiable by pharmacologic agents. In more advanced stages, the contribution of splanchnic vasodilation to portal hypertension increases. 38 In addition, systemic inflammatation on top of sympathetic nervous system-driven hyperdynamic circulation determines the severity of portal hypertension, thus, these "advanced" patients with ascites might be less likely to reponse to carvedilol. The main limitation of this study is the retrospective design.
Thus, our findings should be confirmed in a prospective study. T A B L E 2 Absolute and relative change in parameters between responders and nonresponders (response = decrease in HVPG of ≥ 20% compared to baseline or to HVPG values ≤ 12 mm Hg)
| CONCLUSION
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